The importance of ceruloplasmin oxidase activity in patients with chronic lower limb atherosclerotic ischemia

International Angiology

Volumn 26, Issue 4, 2007, Pages 341-345

  Majewski, W ^a   Iskra, M ^a   Stanisic M ^a   Laciak M ^a   Mackiewicz, A ^a   Staniszewski, R ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

Acute phase proteins; Atherosclerosis; Ceruloplasmin; Ischemia

Indexed keywords

ANALGESIC AGENT; C REACTIVE PROTEIN; CERULOPLASMIN; DIANISIDINE; INTERLEUKIN 6; OROSOMUCOID; OXIDOREDUCTASE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOELECTROPHORESIS; INTERMITTENT CLAUDICATION; LEG ISCHEMIA; MALE; PROTEIN BLOOD LEVEL; RISK FACTOR; SPECTROMETRY; VASCULAR NECROSIS;

ADULT; AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CERULOPLASMIN; CHRONIC DISEASE; HUMANS; INTERLEUKIN-6; ISCHEMIA; LEG; MALE; MIDDLE AGED; OROSOMUCOID; SEVERITY OF ILLNESS INDEX;

EID: 38949110303     PISSN: 03929590     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Visiolo F. Galli C. Evaluating oxidation process in relation to cardiovascular disease: a current review of oxidant antioxidant methodology. Nutr Metab Cardiovasc Dis 1997;7:459-66.
2. Mezzetti A, Guglielmi MD, Pierdomenico SD, Costantini F, Cipollone F, De Cesare D et al. Increased systemic oxidative stress after elective endarterectomy: relation to vascular healing and remodeling. Arterioscler Thromb Vasc Biol 1999;19:2659-65.
3. Harris ED. Regulation of antioxidant enzymes. FASEB J 1992;6:2675-83.
4. Kushner I, Mackiewicz A. Acute phase proteins as disease markers. Dis Markers 1987;5:1-11.
5. Price Anderson C, McCarty LW, editors. Disturbances of circulation. Pathophysiology. Clinical concept of disease progress, 2nd ed. New York: McGraw-Hill; 1982.
6. Klipstein-Grobusch K, Grobbee DE, Koster JF. Serum ceruloplasmin as a coronary risk factor in the elderly: the Rotterdam Study. Br J Nutr 1999;81:139-44.
7. Saenko EL, Yaropolov AI, Harris ED. Biological function of ceruloplasmin expressed through copper binding sites and a cellular receptor. J Trace Elem Exp Med 1994;7:69-88.
8. Floris G, Medda R, Padiglia A, Musci G. The physiopathological significance of ceruloplasmin. Biochem Pharmacol 2000;60:1735-41.
9. Fox PL, Mazumder B, Ehrenwald E, Mukhopadhyay CK. Ceruloplasmin and cardiovascular disease. Free Rad Biol Med 2000;28:1735-44.
10. Ehrenwald E, Fox PL. Role of endogenous ceruloplasmin in low density lipoprotein oxidation by human U937 monocytic cells. J Clin Invest 1996;97:884-90.
11. Iskra M, Majewski W. Copper and zinc concentrations and the activities of ceruloplasmin and superoxide dismutase in atherosclerosis obliterans. Biol Trace Elem Res 2000;73:55-65.
12. Schosinsky KH, Lehmann HP, Beeler MF. Measurement of ceruloplasmin from its oxidase activity in serum by o-dianisidine dihydrochloride. Clin Chem 1974;20:1556-63.
13. Fay GH. Cytokine and acute phase response of the liver. In: Arias IM, Boyer J-L, Fausto N, Jacoby WB, Schachter D, Shafritz DA, editors. The liver: biology and pathobiology, 3rd ed. New York: Raven; 1994.p.113-43.
14. Thor M, Yu A, Swedenborg J. Markers of inflammation and hypercoagulability in diabetic and nondiabetic patients with lower extremity ischemia. Thromb Res 2002;105:379-83.
15. Iijima S, Shiba K, Kimura M, Nagai K, Iwai T. Changes of alphal-acid glycoprotein microheterogeneity in acute inflammation stages analyzed by isoelectric focusing using serum obtained postoperatively. Electrophoresis 2000;21:753-9.
16. Majewski W, Staniszewski R, Slupianek A, Górny A, Mackiewicz A. Acute phase protein (APhP) interleukin 6 (IL-6) serum levels in patients with chronic arterial occlusion. Ann N Y Acad Sci 1995;762:493-5.
17. Majewski W, Zielinski A, Laciak M, Staniszewski R, Gorny A, Zapalski S et al. C-reactive protein and alpha-1-acid glycoprotein in monitoring of patients with chronic arterial occlusion of the lower limbs. Eur J Vasc Surg 1993;7:628-32.
18. Cosin-Sales J, Pizzi C, Brown S, Kaski JC. C-reactive protein, clinical presentation, and ischemic activity in patient with chest pain and normal coronary angiograms. J Am Coll Cardiol 2003;41:1468-74.
19. Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactive-protein-associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther 2002;303:1007-13.
20. Majewski W, Cybulski Z, Napierala M, Pukacki F, Staniszewski R, Pietkiewicz K et al. The value of quantitative bacteriological investigations in the monitoring of treatment of ischaemic ulcerations of lower legs. Int Angiol 1995; 14:381-4.
21. You SA, Wang Q. Ferritin in atherosclerosis. Clin Chim Acta 2005;357:1-16.
22. Suciu I, Negrean V, Sampelean D. The oxidative stress in the development of diabetes chronic complications in the elderly. Rom J Intern Med 2004;42:395-406.
23. Lopes PA, Napoleao P, Pinheiro T, Ceia F, Steghens J-P, Pavao ML et al. ystemic markers of the redox balance and apolipoprotein E polymorphism in atherosclerosis: the relevance for an integrated study. Biol Trace Elem Res 2006;112:57-75.
24. Memisogullari R, Bakan E. Levels of ceruloplasmin, transferrin, and lipid peroxidation in the serum of patients with Type 2 diabetes meilitus. J Diabetes Complications 2004;18:193-7.
25. Tungtrongchitr R, Pongpaew P, Phonrat B, Supawan V, Chanjanakitskul S, Vudhivai N et al. The effect of cigarette smoking on cerufloplasmin and C3 complement: risk of cardiovascular disease (atherosclerosis). Asian Pac J Allergy Immunol 2002;20:23-8.